This work investigates a new type of polyelectrolyte complex nanocarrier composed of hyaluronic acid (HA) and protamine (PROT). Small (approximately 60 nm) and negatively charged nanoparticles (NPs) with a polydispersity index of less than 0.2 were obtained with properties that were dependent on the mixing ratio, concentration of polyelectrolytes and molecular weight of HA. Salmon calcitonin (sCT) was efficiently (up to 100%) associated with the NPs, and the drug loading (9.6-39% w/w) was notably high, possibly due to an interaction between HA and sCT. The NPs released ~70-80% of the sCT after 24 hours, with the estimated total amount of released sCT depending on the amount of HA and PROT present in the NPs. The isoelectric point of the NPs was close to pH 2, and the negative surface charge was maintained above this pH. The HA/PROT nanoplexes protected the sCT from enzymatic degradation and showed low toxicity to intestinal epithelial cells, and thus may be a promising oral delivery system for peptides.
Introduction
It has been demonstrated that it is possible to form HA-based polyelectrolyte-complex NPs, but most of the work conducted thus far has focused on HA/chitosan NPs 1,2,3,4 .
However, as a polyanion, HA has the ability to form polyelectrolyte complexes with other polycations. Among these materials, polypeptides and proteins are of great interest because of their biodegradability and biocompatibility. For instance, complexes of HA based on electrostatic attraction with poly-L-lysine 5 and lysozyme 6, 7 have been formulated and examined. Reports have been published on complexation of HA with poly-arginine, resulting in the formation of polyelectrolyte-complex NPs. 8, 9 Both research groups obtained small NPs with sizes of approximately 90-170 nm that were positively 8, 9 or negatively charged. 9 Kim et al. used these NPs as carriers for delivery of siRNA. 8 Oyarzun-Ampuyero et al. successfully
produced NPs via simple mixing of polycation and polyanion solutions, and no cross-linker was used. 9 Although this group indicated that incorporation of hydrophilic macromolecular drugs, e.g., peptides, into their nanocarriers may be possible, no such studies have been published thus far. Additionally, the high cost of polyarginine may be one of the disadvantages of its use in drug delivery.
Hence, another polycation is required that could be complexed to HA to produce NPs.
Ideally, such a compound should be reasonably inexpensive, already well characterized and
should have a history of use in pharmaceutical products, thus minimizing the need for additional biodegradability and toxicity studies. Protamine (PROT) can be considered as a promising candidate because it is a naturally occurring and strongly charged cationic protein and already used in formulations that contain insulin. 10 Additionally, PROT is used as a drug itself in applications as an antagonist for heparin. Similar to certain viral proteins that use arginine-rich sequences of amino acids to provide membrane-translocation activities, PROT consists of a mixture of positively charged proteins extracted from salmon roe and is rich in arginine,. Indeed, Reynolds et al. showed that PROT displays membrane translocation activity, which is a desirable property for protamine-based formulations intended for use in pharmaceutical applications. 11 Moreover, protamine offers a long history of use and established biological effects and general safety in humans. 11 Junghans et al. showed that complexation to protamine protected oligonucleotides from enzymatic degradation and increased their cellular uptake. 12 Additionally, PROT has been shown to form polyelectrolyte complexes NPs with heparin and with a glycosaminoglycan such as HA but with a higher charge density. Mori et al. succeeded in producing polyelectrolyte-complex micro-and nanoparticles containing heparin and PROT as a carrier for fibroblast growth factor-2 (FGF-2). 13 The NPs appeared to maintain the mitogenic activity of FGF-2 and protect the peptide from inactivation by heat.
Both HA and PROT have been combined in a sustained release delivery system. Minipellets composed of HA/recombinant human interleukin 11 (rhIL11) and HA/PROT/rhIL11
were observed to enhance the in vivo efficacy of the cytokine, which was attributed to the interactions between HA and rhIL11. 14 A longer plasma residence time was measured for rhIL11 released from HA/PROT pellets, which was accompanied by an increase in pharmacologic efficacy. 14 Mok et al., showed that a conjugate of HA and an anti-sense oligonucleotide used to form a nanocomplex with PROT was characterized by better cellular uptake compared with that of unconjugated physical complexes formed between PROT and naked oligonucleotides. 15 We recently presented studies on the optimum formation condition and properties of crosslinker-and surfactant-free HA/chitosan NPs 4 and also showed that salmon calcitonin/HA/chitosan NPs were able to reduce experimental inflammatory arthritis. 16 Because HA and sCT produced important anti-inflammatory effects in vitro 16 , an HA-based delivery system appears to be a particularly suitable carrier for sCT. Calcitonin is currently 5 recommended for short-term use in Paget's disease, acute bone loss due to sudden immobilization and hypercalcaemia caused by cancer.
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Considering that no nanosized drug delivery system based on HA and PROT has been reported to date, the aims of the current work were to investigate the conditions of such nanocarrier formation by adopting the previously presented manufacturing process 4 , to evaluate the properties of NPs formation and to explore the ability of HA/PROT NPs to bind, release and protect sCT.
Materials and methods

Materials
Hyaluronic acid sodium salt (HA) from Streptococcus equi sp. and protamine sulfate (PROT, molecular weight of 5.1 kDa; manufacturer data) were purchased from Sigma (USA).
Pepsin from porcine gastric mucosa (cat. no. P6887, 4220 IU/mg) and trypsin from bovine pancreas (cat. no. T8003, 12238 BAEE/mg) were sourced from Sigma Aldrich (Ireland).
Salmon calcitonin (sCT) was obtained from PolyPeptide Laboratories (Denmark), APC annexin V and propidium iodide were obtained from BD Biosciences (USA) and CellTiter 96 ® Non-Radioactive Cell Proliferation Assay was purchased from Promega Corporation (USA). Other cell culture reagents were provided by Sigma Aldrich (Ireland). All other reagents, chemicals and solvents were of analytical grade.
Preparation of HA/PROT carriers and HA/PROT/sCT NPs
The HA solutions with concentrations of 0.1 or 0.2% w/v were prepared in deionized water, and HA with molecular weights of 176 kDa, 257 kDa and 590 kDa (later referred to as HA176, HA257 and HA590, respectively) were obtained via ultrasonication of native HA (2882±24.5 kDa), as previously described. 4 The PROT solutions with concentrations of 0.2-3.2 mg/ml were also prepared using deionized water.
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The NP carriers (NPs without the cargo) were formed by adding 4 ml of an aqueous PROT solution to 10 ml of an HA solution at room temperature under magnetic stirring. The stirring was maintained for 10 minutes to allow stabilization of the system. A dispersion of particles was instantaneously obtained upon mixing of the polymer solutions. Because PROT solutions with different concentrations were used, the NP dispersions that were formed had different compositions of HA (equivalent to 0.71 mg/ml or 1.43 mg/ml in the final formulation) and PROT (equivalent to 0.06-0.91 mg/ml in the final formulation). The PROT weight fraction in the HA/PROT NPs was calculated as the ratio of the weight of PROT to the total weight of HA and PROT used to form a given system.
The NPs containing sCT were formed by following the above procedure with a modification for an appropriate quantity of the peptide, resulting in a final sCT concentration in the NP dispersion of 0.1 mg/ml, 0.5 mg/ml and 1.0 mg/ml (equivalent to 1.4 mg, 7.0 mg and 14.0 mg of sCT in 10 ml of HA solution, respectively) as dissolved in the HA solution prior to mixing with the PROT solution.
NPs characterization and stability
Transmittance measurements
The transmittance of the NP dispersions was measured using an UV-1700
PharmaSpec UV-Visible spectrophotometer (Shimadzu, Japan) at an operating wavelength of 500 nm in optically homogenous quartz cuvettes (Hellma, Germany) with a light path of 10 mm. 
Particle size and zeta potential analysis
The intensity-averaged mean particle size (hydrodynamic particle diameter) and the polydispersity index of the NPs were determined using Dynamic Light Scattering (DLS) with 173º backscatter detection. The electrophoretic mobility values measured by Laser Doppler Velocimetry (LDV) were converted to zeta potentials using the Smoluchowski equation. Both the DLS and LDV measurements were collected on a Zetasizer Nano series Nano-ZS ZEN3600 fitted with a 633-nm laser (Malvern Instruments Ltd., UK). Samples were placed directly into the folded capillary cells without dilution. Each analysis was carried out at 25ºC
with the equilibration time set to 5 minutes. The readings were repeated at least three times for each batch, and the average values of at least three batches are presented. The results obtained were corrected for the sample viscosity measured at 25±0.2ºC with a low frequency vibration viscometer (SV-10 Vibro Viscometer, A&D Company Limited, Japan). 
Transmission electron microscopy (TEM)
The TEM image collection was performed with a JEM-2100 instrument (Jeol, USA), as described previously. 4 One drop of NP suspension was deposited onto a copper grid, held for 60 seconds and the excess liquid was blotted off using filter paper. The immobilized samples were stained by deposition of one drop of 1% w/v ammonium molybdate solution for 60 seconds. The excess liquid was again blotted off using filter paper, and the grids were dried overnight for viewing with TEM. The acceleration voltage was 200 kV.
Scanning electron microscopy (SEM)
The SEM collection was carried out with a Supra Variable Pressure Field Emission Scanning Electron Microscope (Zeiss, Germany) equipped with a secondary electron detector at 2 kV. 18 An amount of 50 µl of liquid sample was directly placed onto an aluminum stub, dried for 24 hours at ambient temperature in a desiccator over silica gel and sputter-coated with gold under vacuum prior to analysis.
pH measurements
A pH meter (Orion model 520A, Thermo Scientific, USA) equipped with an Orion Ross™ 8103SC glass-body pH semi-micro electrode was used for the pH measurements. The pH meter was calibrated using standard buffer solutions (Thermo Scientific, USA) of pH 4.00, 7.00 and 10.00 (±0.01). 8
Physical stability of nanoparticles
Physical stability studies of the NPs in native and undiluted dispersions were performed in polypropylene tubes upon storage at room temperature for a period of up to 4 weeks in a dark environment. Samples from each formulation were withdrawn periodically during the studies, and the particle size, zeta potential and transmittance were measured.
Determination of the isoelectric point of NPs
A Zetasizer Nano series Nano-ZS ZEN3600 particle sizer fitted with a 633-nm laser together with a MPT-2 autotitrator (Malvern Instruments Ltd., UK) were used to determine the isoelectric point of the NPs. 4 Amounts of 0.25M HCl and 0.25M NaOH were used as titrants. A total of 12 ml of NP dispersion was added initially to the sample container. Each analysis was carried out at room temperature in automatic mode using the target pH tolerance of 0.2 units. Three particle size measurements and three zeta potential measurements were carried out for each pH value, and the samples were re-circulated between repeat measurements.
Salmon calcitonin (sCT) loading studies
Separation of non-associated sCT
Non-associated sCT was separated from the NPs using a combined ultrafiltrationcentrifugation technique (Centriplus YM-50, MWCO of 50 kDa, Millipore, USA). 16 A total of 5 ml of sample was placed in the sample reservoir (donor phase) of the centrifugal filter device and centrifuged for 1 hour at 4,537 g (3,000 rpm). After centrifugation, the volume of the solution in the filtrate vial (acceptor phase) was measured, and the filtrate was assayed for sCT content via HPLC, as described below. This quantity of sCT was referred to as the nonassociated sCT.
The NP suspension from the sample reservoir was standardized to 5 ml with deionized water. A total of 0.75 ml of the NP suspension from the sample reservoir was mixed with 0.75 ml of 0.1 mM NaOH (this NaOH concentration was optimized and did not cause sCT degradation) to break up the NPs and release sCT, and the mixture was centrifuged for 30 minutes at 16,060 g (13,000 rpm). The supernatant was assayed for sCT content via HPLC, and this portion of the peptide was referred to as the extracted sCT. A good mass balance of sCT was obtained if it were possible to extract more than 90% of the associated sCT. The remainder of the dispersion from the sample reservoir was analyzed for particle size, zeta potential and transmittance. The particle size, zeta potential and transmittance and the pH and viscosity of the nanoparticles before separation of the non-associated sCT were also measured.
The association efficiency (AE) and drug loading (DL) were calculated using the following equations:
where A is the total amount (mass) of the sCT, and B is the mass of the non-associated sCT
where C is the total weight of all components of the NPs (the associated sCT and the mass of HA and PROT used for the preparation of NPs).
Release studies
Aliquots of 250 µl of NPs were added to 2.25 ml of PBS (137 mM NaCl, 2.7 mM KCl, 1.4 mM NaH 2 PO 4 , 1.3 mM Na 2 HPO 4 adjusted to pH 7.4 with NaOH solution). The samples were incubated at 37ºC at 100 cpm in a reciprocal shaking water bath (model 25, Precision Scientific, India). After 1, 2, 4, 6 and 24 hours, 2.5 ml aliquots were withdrawn, and the released sCT was separated using the combined ultrafiltration-centrifugation technique as described above. The samples were centrifuged at 6,805 g (4,500 rpm) for 15 minutes. After centrifugation, the volume of the solution from the filtrate vial (acceptor phase) was measured, and the filtrate was assayed for sCT content via HPLC (released sCT; the HPLC method is described below). The NP suspension from the sample reservoir was standardized to 2.5 ml with PBS and returned to the water bath to continue the release studies. 16 The data from the release studies were fitted to the first-order equation:
where W is the total amount of the peptide released at time t (based on cumulative release), W ∞ is the amount of the peptide released at infinity and k is the release rate constant. 
Quantification of sCT
Analysis of sCT content was performed using an HPLC system as described previously. 16 Briefly, standard solutions of sCT (1.5-50 µg/ml) were prepared in deionized water, and 50 µl of the standard or sample was injected into the Jones Chromatography Genesis 4µ C18 150 × 4.6 mm column (Crawford Scientific Ltd, UK). A flow rate of 1 ml/min was employed using a mobile phase composed of 0.116% w/v NaCl, 0.032% v/v TFA, and 34% v/v acetonitrile. The UV detection was carried out at 215 nm. The sCT peak had a retention time of ~5 min. Data collection and integration were accomplished using CLASS-VP software (version 6.10, Shimadzu, Japan).
Enzymatic degradation of sCT
Stability analysis of sCT in the presence of pepsin and trypsin was carried out using a HA/PROT NP system with an MMR of 6.3 and an sCT loading of 0.2 mg/ml as well as 0.2 mg/ml sCT solution (made up in 0.9% NaCl). A pepsin stock solution with a concentration of 20,000 IU/ml was prepared in pepsin-free simulated gastric fluid (SGF, HCl solution with pH 1.2 containing 0.2% w/v NaCl, Ph. Eur. 7 th edition 20 ). The trypsin stock solution (2,900 BAEE/ml) was prepared in phosphate buffered saline (PBS, pH 7.4).
For the experiments with pepsin, 2.5 ml of NPs-sCT or sCT solution was mixed with 2.5 ml of SGF and 50 µl of pepsin stock solution such that the initial concentrations of sCT and pepsin were 0.1 mg/ml and 200 IU/ml, respectively. The control sample was prepared with 2.5 ml of NPs-sCT or sCT solution, 2.5 ml of SGF and 50 µl of SGF (pepsin-free). For the experiments with trypsin, 2.5 ml of NPs-sCT or sCT solution was mixed with 2.5 ml of PBS and 12 µl of trypsin stock solution such that the initial concentrations of sCT and trypsin were 0.1 mg/ml and 7 BAEE/ml, respectively. The control sample was prepared with 2.5 ml of NPs-sCT or sCT solution, 2.5 ml of PBS and 12 µl of PBS. All samples, controls and enzyme-containing mixtures were incubated at 37°C.
At given time intervals, 0.7 ml of the sample was withdrawn from each mix, and the enzymatic reaction was stopped by addition of 0.1 ml of 1M NaOH (to samples with pepsin and controls for experiments with pepsin) or 0.1 ml of 1M HCl (to samples with trypsin and controls for experiments with trypsin). The 0.8-ml aliquots were centrifuged at 16,060 g (13,000 rpm) for 5 min at 4°C, and the amount of sCT remaining in the supernatant was determined via HPLC, as described in Section 2.4.3.
Cell culture and in vitro cytotoxicity studies
Human colon adenocarcinoma cells (Caco-2) were obtained from the European
Collection of Cell Cultures. Cells were cultured as a monolayer in Eagle's Minimal Essential Medium (MEM) supplemented with 20% fetal bovine serum (FBS), penicillin (0.006 mg/ml), streptomycin (0.01 mg/ml), gentamicin (0.005 mg/ml), sodium bicarbonate (2.2 g/l) and sodium pyruvate (0.11 g/l) in a 5% CO 2 and 37ºC humidified atmosphere (CO 2 incubator series 8000DH, Thermo Scientific, USA). Cells were supplied with fresh medium every second day and split after detachment with EDTA-trypsin twice a week. For experimental purposes, the passage number range was maintained between 20 and 30.
MTS assay
The Caco-2 cells were seeded into flat-bottom 96-well plates in 100 µl of MEM containing 20% FBS at a density of 25,000 cells per well and incubated at 37ºC for one day. 
Flow cytometry
The Caco-2 cells were incubated with 3 ml of sample for 72 h. Next, the supernatant was removed, and the cells were harvested with 1 ml of trypsin/EDTA. After neutralization individual events. Data were analyzed using the BD FACSArray TM system software and expressed as a percentage of control fluorescence in arbitrary units.
Statistical analysis
The statistical significance of the differences between samples was determined using one-way analysis of variance (ANOVA) followed by the post-hoc Tukey's test using Minitab software (version 14, Minitab, USA). Differences were considered significant at p<0.05.
3.Results and discussion
HA/PROT nanoparticles: Formation and formulation variables
Higher concentrations of PROT and lower HA/PROT mass mixing ratios (MMRs)
generally resulted in the formation of more turbid systems (Fig. 1A) . Samples produced using a solution with a higher HA concentration (1.43 mg/ml) were generally less transparent than those produced using a solution with lower HA concentration (0.71 mg/ml). Phase separation (detected visually as particle flocculation) was observed for an HA/PROT MMR of 1.4 (0.42
PROT weight fraction, PROT concentration of 0.51 mg/ml) and 1.6 (0.39 PROT weight fraction, PROT concentration of 0.91 mg/ml) when HA solutions with concentrations of 0.71 and 1.43 mg/ml, respectively, were used.
The effect of the molecular weight of HA on the transmittance of the formulations was also investigated. Transmittance values of the 0.71-mg/ml HA-based NPs did not differ significantly when HA with different molecular weights of 590 kDa, 257 kDa and 176 kDa were used (Fig. 1A) . However, when native HA (as supplied) with a molecular weight of 2882±24.50 kDa was used, the formation of microparticles and/or quick-sedimenting NP aggregates was observed when lower PROT concentrations (e.g., 0.06 mg/ml or 0.11 mg/ml, equivalent to an HA/PROT MMR of 12.5 and 6.3 of PROT, respectively) were used. As previously presented by Umerska et al., NP aggregates developed when HA reacted with another polycation or chitosan due to the high molecular weight HA (1161 kDa and above) and high viscosity of its solution. 4 The hydrodynamic diameter of the HA/PROT NPs increased gradually with the increasing amount of added protamine (Fig. 1B) . Neither the molecular weight (between 590 kDa and 176 kDa) nor the concentration of HA (0.71 mg/ml or 1.43 mg/ml) appeared to have a significant effect on the size of the particles formed. It is noteworthy that the HA/PROT NPs appear as rather small polyelectrolyte-complex NPs with sizes well below 100 nm in certain systems. To the best of our knowledge, the complexation of HA to PROT described in this work resulted in the formation of one of the smallest HAbased polyelectrolyte complex NPs (58±18 nm for an HA/PROT MMR of 12.5; HA257).
Kim et al. succeeded in producing HA-containing (HA with a molecular weight of 19 kDa)
NPs smaller than 100 nm (89±12 nm) via complexation to polyarginine. 8 Mayer et al.
highlighted that substitution of protamine-free base by protamine sulfate greatly reduced the size of oligonucleotide-protamine-albumin nanoparticles from 200 nm to approximately 40 nm (43 and 48 nm by sedimentation velocity analysis and 40 nm by atomic force microscopy). 22 Additionally, Mok et al. showed that the particle size of the NPs was reduced from 654 nm to 166 nm when HA was first conjugated to oligodeoxynucleotides and subsequently complexed with protamine compared with the NPs from a system formed by complexing naked oligodeoxynucleotides with HA and protamine 15 . Other HA-complex NPs with polyarginine 9 and chitosan 1, 4 reported to date were significantly larger than 100 nm in diameter.
The transmittance, which gives information on the turbidity of the sample, depends on the concentration and the particle size of the nanocomplexes. An increase in the particle size ( The formulations presented in Fig. 1 showed negative surface potentials, and thus attempts were carried out to obtain positively charged particles because they could be promising carriers for encapsulation/adsorption of negatively charged macromolecules.
Experiments showed that after mixing 1 mg/ml of PROT and 1 mg/ml of 176-kDa HA solutions at an HA/PROT MMR of 0.2, it was possible to obtain small and homogenously dispersed nanoparticles (with initial values for PS and PDI of 252±2.3 nm and 0.065±0.003, respectively); however, their surface charge was notably low (5.5-7 mV), and sedimentation occurred after a few hours of storage at room temperature. Fig. 2 shows the kinetics of aggregation of these particles; the particle size increased rapidly at first within ~2 hours and subsequently reached a plateau for up to 20 hours of storage (Fig. 2) . After 22 hours of storage, the presence of micron-size aggregates was evident from the DLS measurements.
However, the PDI value increased rapidly from 0.065±0.003 to 0.187±0.006 after 30 minutes, and small variations in the DPI values were observed for the next ~2.5 hours, followed by a dramatic increase to 0.592±0.099 after another 17 hours of storage, accompanied by visible aggregation of the particles (Fig. 2) . The values of the zeta potential fluctuated between ~7.3 mV and 5.5 mV and did not change significantly after 22 hours.
In contrast with the results presented above, physically stable and positively charged
NPs were formed when HA and polyarginine 8, 9 were used together with HA and chitosan 4 . A possible explanation might be the largely different molecular weights of the components used because the molecular weight of HA used in the positively charged NPs was ~35 times higher than the molecular weight of the major component of protamine (5.1 kDa based on manufacturer's data). According to Boddohi et al., when the polyelectrolyte in excess (protamine in this case) has a much lower molecular weight than the other polymer (HA), a more compact morphology results, leading to flocculation of the NPs in certain cases and poor colloidal stability. 23 However, the difference in charge density together with the difference in molecular weight also may be an important factor that causes the poor stability of positively charged HA/PROT NPs. Schatz et al. examined polyelectrolyte complexes composed of chitosan and dextran sulphate. 24 When these researchers mixed a high-Mw chitosan (365 kDa) and a low-Mw dextran sulfate (5 kDa), the situation was similar to that described above: the polyelectrolyte pair was composed of long molecules with a low charge density and small molecules with a high charge density. When chitosan was used in excess, stable and positively charged particles were obtained; however, when dextran sulfate was used in excess, the negatively charged polyelectrolyte complexes showed poor colloidal stability. Nonetheless, the positively charged polyelectrolyte complexes between HA and polyarginine obtained by Oyarzun-Ampuyero et al. were reported as stable despite the large differences in charge density and chain length of both molecules. 9 The ratio of the molecular weight of the components used by Schatz et al. 24 was 73, that used by Oyarzun-Ampuyero et al. 9 was 11-33, and that of the HA/PROT NPs in the current work was 35.
Another difference between the HA/PROT complex and other polyelectrolyte complexes (e.g., HA/chitosan 3, 4 , heparin/chitosan 3 
Morphology of HA/PROT NPs
Transmission electron micrographs show that the HA/PROT NPs (Fig. 3) were approximately spherical in shape. In certain cases, deformations were observed. However, in contrast with the HA/chitosan chloride NPs 4 , no core and corona structure was observed in the HA/PROT NPs. The particles composed of HA (0.71 mg/ml) and PROT (0.11 mg/ml, HA/PROT MMR=6.3) had sizes of approximately 20 nm to 30 nm (Fig. 3A) . Differences in the particle size between the DLS and TEM data are due to the different principles of measurement for both methods and possible modification of a subset of the properties of the particles during sample preparation for TEM, primarily as a result of water removal, as observed previously. 25 In the sample containing additional PROT (0.34 mg/ml) and therefore a smaller ratio of HA to the polycation, the particles observed in the TE micrographs were approximately 100-200 nm in size (Fig. 3B ). 
Isoelectric point of HA/PROT nanoparticles
The IEP values of selected HA/PROT NPs are shown in Table 1 does not seem to affect the pH at which the charge of the NPs is neutralized. A similar trend, (i.e., dependence of IEP on the polyanion/polycation mixing ratio) was observed in previously described HA/chitosan NPs. 4 The IEP values of HA/PROT NPs were comparable with those of HA/chitosan NPs with similar MMRs. 5A ). After four weeks of storage, however, the FA became more transparent, and a significant increase was observed in the transmittance values between weeks 3 and 4, which may be attributed to sedimentation of aggregating particles.
The particle sizes of FA and FB increased gradually and significantly for the first three weeks of storage, whereas the size of the particles in formulation FC remained unchanged (Fig. 5B) . The increase in the particle size occurred earlier for FA compared FB; however, even after three weeks of storage, the FA particles were still significantly smaller than those of FB. After four weeks of storage, a significant increase in the particle size was observed for all formulations tested and was especially pronounced in FA. The PDI of FA and FB decreased noticeably in the first days of storage, whereas the PDI of FC generally remained steady up to three weeks of storage. However, after the fourth week of storage, a significant decrease in the homogeneity of the NPs of all three formulations was observed, which corresponds to the increase in the particle size (Fig. 5C ).
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The surface charge of the particles became less negative during storage, and the increase was most pronounced in formulation FA (Fig. 5D ). After two weeks of storage, the zeta potential values of FA, FB and FC were all significantly different from one another, but there was no statistically significant difference between FA and FB after three weeks. After four weeks, there was no significant difference between all three formulations.
Although the NPs appeared to be relatively stable after one or even two weeks of storage, it can be observed that the systems are dynamic. It is likely that the particles interacted, leading to changes and re-organization in their structures. The PROT NPs were found to be less stable than the previously described HA/chitosan NPs. 4 This difference is especially pronounced for positively charged NPs (see Section 3.1) and may be due to the fact that the charge density of the polycations is different and that the molecular weight of chitosan is over 20-fold greater than that of PROT. Interestingly, the PROT/oligonucleotide nanoparticles described by Junghans et al. with mean diameters of 150-170 nm doubled their size after three days, reaching diameters of approximately 300 nm. 12 The formulation tested by Junghans et al. had a positive surface charge, and no data on the stability of negatively charged PROT/oligonucleotide NPs were provided. Table 2 shows the composition of the sCT-loaded HA257/PROT nanoformulations tested. The formulations containing different concentrations of HA and PROT were selected to examine the influence of HA and PROT concentration and their mixing ratios on the properties of the sCT-containing NPs. In addition, different concentrations of sCT were used to examine the effect of this variable on the formation and properties of the NPs. Dispersions with an HA/PROT MMR=1.8 (containing the greatest proportion of PROT) were not considered as viable delivery systems because they were not physically stable due to their low surface charge. The properties of the sCT-loaded NPs investigated are presented in Table 2 .
Formation and characterization of sCT-loaded HA/PROT NPs
Similar to the HA/PROT NPs without sCT, the higher the concentration of PROT, the lower the transmittance measured (Table 2 ). Low concentrations of sCT (0.1 mg/ml) did not have a significant influence on the turbidity of the dispersions, but when the concentration of sCT was increased to 0.5 mg/ml or 1 mg/ml, it was evident that the formulations became less transparent. Additionally, the increase in the HA concentration led to the formation of more turbid HA/PROT/sCT systems, and the formulations based on 1.43-mg/ml HA solutions were characterized by lower transmittance values compared with those of the equivalent 0.71-mg/ml HA-based formulations ( Table 2 ).
The presence of sCT in the particles had a considerable impact on their properties. An increase in the amount of sCT markedly increased the size of the particles (Table 2) increased PDI values. This increase was accompanied by an increase in the particle size and was observed after a few hours precipitation.
Incorporation of sCT into the NPs decreased the surface charge of the particles in a concentration-dependent manner; however, all formulations remained negatively charged (Table 2 ). This observation may indicate that an amount of sCT was deposited on the surface of the particles. Nevertheless, many formulations (especially those with low sCT content)
were still characterized by a highly negative surface charge, even after incorporation of the peptide into the NPs. In certain cases, loading of sCT led to an increase in the zeta potential to values close to -20 mV, and this rise was especially pronounced in formulations containing higher amounts of PROT. Table 1 shows that a loading of 0.5 mg/ml of sCT did not affect the isoelectric point of the 0.71-mg/ml HA-based formulation with an HA/PROT MMR of 6.3.
Therefore, sCT could be safely loaded into the NPs that contained a low amount of PROT without significantly changing their behavior in acidic environments.
As shown in Table 2 , sCT was successfully associated with the HA/PROT nanoparticles. The association efficiency (AE) values were quite high (most were greater than 90%) and can be considered as one of the highest value reported thus far for sCT. Certain authors managed to obtain AE values higher than 90% (e.g., Yang et al. 27 ), but many authors which were deemed unstable and in which precipitation was observed after a few hours of storage. These formulations were also susceptible to precipitation during separation of nonassociated sCT via ultrafiltration-centrifugation.
In conclusion, because sCT has a destabilizing effect on the NPs, especially when used at high concentrations (e.g., 1 mg/ml), it is necessary to compensate for this effect using low PROT concentrations.
sCT release studies from HA/PROT nanoparticles
The results of in vitro release studies are shown in Fig. 6 . The release profiles of sCT may be considered similar for all formulations tested. Although the percentage of sCT released from F6 was slightly lower, even in this case, the difference was not statistically significant. Formulation F6 was one of the most unstable formulations (the particles aggregated quickly in PBS to form entities with sizes of 623±87 nm), and it is possible that sCT was irreversibly bound to the aggregated fraction. No aggregation or flocculation was observed for other samples tested in the release medium (PBS), and the particle size of the systems decreased in general, suggesting a degree of NP dissolution. For instance, the F3 particle size decreased from 211±28 nm to 159±6 nm and that of F11 was reduced from 505±133 nm to 244±24 nm.
Approximately half of the sCT dose loaded into the NPs was released in the first 2 hours, and up to approximately 70-80% of sCT was released after 24 hours (Fig. 6 ). The release of sCT from the HA/PROT NPs is relatively rapid compared with other delivery systems that are capable of providing release of proteins for days. 33 The rate of protein release from ionic hydrogels is influenced by the various structural parameters of the protein and polyelectrolyte as well as the environmental conditions inside hydrogel. 34 Proteins with low molecular weights are generally characterized by faster release rates. 34 Additionally, Kamiya and Klibanov examined the release of lysozyme from its complexes with different polyanions. 35 These researchers confirmed that the protein was gradually released from its non-covalent and water-insoluble complex with the oppositely charged poly-ion over a period of hours or days, and the rate of in vitro release was markedly dependent on the nature of the polyion. Polymers with higher charge density were found to provide slower release of lysozyme. Because HA has rather low charge density and sCT is a peptide with low molecular weight, it is expected that most of the sCT release would occur within a few hours.
The release data were fitted to a first-order equation (Eqn. 3, Section 2.4), and the parameter estimates obtained are summarized in Table 3 . For the 1-mg/ml sCT, sample F3
(HA/PROT MMR of 6.3, HA concentration of 0.7 mg/ml) had the largest W ∞ , and statistically significantly lower W ∞ values were obtained for NPs with an HA/PROT MMRs of 4.2 (F8) and 3.1 (F9) (HA concentration of 1.4 mg/ml). These results are therefore in agreement with the above observation that superior sCT carriers consist of those with low PROT content. When 0.5-mg/ml sCT was used, the W ∞ were observed to be significantly different for samples based on 0.71-mg/ml HA with an MMR of 6.3 (F2) and 2.1 (F6).
Comparison of the release data from samples with the same MMR (3.1) and different HA concentrations revealed that the W ∞ values were statistically significant and greater for NPs composed of 0.7-mg/ml HA than those prepared from 1.4-mg/ml HA. Therefore, it appears that the additional HA present in NPs is able to bind more sCT, and thus the total amount of sCT released is lower. Greater amounts of PROT result in greater W ∞ values, consistent with the hypothesis of species competition (PROT versus sCT) in binding with HA.
Analysis of the release data led to the conclusion that the driving force for release of sCT was initially dissolution of the NPs (break-up of complexes due to the higher ionic strength of PBS) and diffusion of the peptide across the NP matrix due to the concentration gradient. However, as indicated by the W ∞ values (Table 3) , a certain amount of sCT remained strongly complexed to HA and was not released under the conditions of the experiment.
Effect of formulation on enzymatic degradation of sCT
As shown in Fig. 7 , the sCT was not degraded in all control samples if no enzyme were present. The amount of intact peptide was not statistically different if comparing the quantity of peptide recovered from the sCT solutions and NP formulations at the different time points. In the presence of pepsin, the stability of sCT in the NPs was significantly improved up to 60 min of incubation ( minutes of the experiment) when exposed to the enzyme for 30 min or longer (Fig. 7B) .
Therefore, it can be concluded that the formulation can protect the peptide in vitro from enzymatic degradation by pepsin and trypsin. Lee et al. reported on the preparation and characterization of an sCT-sodium triphosphate ionic complex for oral delivery of the peptide and observed that the complex protected the sCT from enzymatic cleavage by pancreatin 36 .
Thus, it appears that polyelectrolyte complexes can be robust and have protective effects on the associated peptide.
The PROT has been reported to translocate itself into several mammalian cell lines quite efficiently in 30 minutes. 37 In addition, studies showed that PROT was able to carry a peptide gelonin (a plant toxin of approximately 30 kDa) across the membrane after 30 min of incubation of the peptide with CT-26 cells. 37 Furthermore, because HA exhibits mucoadhesive properties in the intestinal environment 38 , it can be expected that an intimate contact would be formed 39 between the intestinal mucosa and the nanoparticle, therefore further avoiding degradation of sCT on the path between the carrier and the membrane. Thus it is expected that even though short in duration, the protective effects of NPs may translate into a real therapeutic effect.
Cytotoxicity studies
The cytotoxicity of the PROT and NPs was examined in Caco-2 cells to assess any potential toxic interactions with cells. As mentioned previously, HA was not toxic to Caco-2 cells even at a concentration of 5 mg/ml. 4 An MTS assay and flow cytometry showed that PROT exerts concentration-dependent toxic effects in Caco-2 cells (Fig. 8A) . The MTS assay was more sensitive than flow cytometry (IC 50 of 0.24±0.01 and 0.52±0.03 mg/ml, respectively). It can be observed from apoptosis assay results (Fig. 8B ) and the scatter plots ( which also depends on the activity of mitochondrial dehydrogenase of the cells, similar to MTS. 15 The maximum concentration of PROT tested (160 µg/ml) did not affect the viability of the cells after 24 hours of incubation. We observed a significant decrease in the viability of cells determined via MTS assay at a PROT concentration of 125 µg/ml ( Fig. 8A and 9) . The difference may be explained by the markedly longer incubation time (72 hours) used in the current studies and by the use of a different cell line.
The NPs selected for cytotoxicity studies by MTS assay had an HA/PROT MMR of 3.1. This dispersion was stable even after dilutions with medium containing a concentration of PROT sufficiently high to produce a toxic effect on the Caco-2 cells such that a comparison could be carried out on the effects of PROT and HA/PROT NPs. At the highest concentration of NPs possible to achieve for this formulation, i.e., 0.78 mg/ml of NPs (which contains 0.25 mg/ml of PROT), the viability of the cells was decreased significantly (70.31±15.65% of viable cells) compared with that of serum-free medium (Fig. 9 ).
The cell viability was comparable after treatment with 0.25 mg/ml of PROT and NPs containing 0.25 mg/ml PROT (Fig. 9 ). Therefore, it can be suggested that HA present in the NPs exerts a protective effect on Caco-2 cells against the negative influence of PROT, as previously observed for HA/chitosan NPs. 4 The protective effects of HA against the toxicity of another polycation, i.e., polyarginine, have been demonstrated by Kim et al. 8 This group showed that HA/polyarginine nanoparticles were markedly less toxic compared with polyarginine on its own and that increasing the HA content in the formulation further reduced their toxicity.
Summary and conclusions
In this work, a new type of nanoparticle carrier was successfully developed that incorporates HA and PROT into its structure. The formation and characteristics of the particles depend on the conditions used, e.g., the concentration of both polyelectrolytes and 29 their MMR, and also on the molecular weight of HA used. Positively charged nanoparticles
were not stable upon storage at room temperature in contrast with dispersions containing negatively charged particles. By modulation of the formulation conditions, it was possible to produce NPs with good micromeritic properties, i.e., monodispersed and with a notably small size. A subset of the nano-suspensions was characterized by a particle size below 100 nm, which can be considered quite small for polymeric nanoparticles. Indeed, the smallest particles containing HA590 and PROT at an HA/PROT MMR of 13 were characterized by an average hydrodynamic diameter of 58±18 nm.
Additionally, most of HA/PROT dispersions tested had an isoelectric point close to a pH of 2, and therefore, it appears that these particles will be stable and will maintain their negative surface charge at neutral and slightly acidic pH values. The HA/PROT NPs showed low toxicity to Caco-2 cells.
The HA/PROT NPs appear to be a promising system for the delivery of sCT because they are characterized by an excellent capacity for loading high doses of sCT and providing prolonged release and protection from enzymatic degradation of this peptide. By optimizing the composition of the nanoparticles, it was possible to obtain sCT-loaded NPs that maintained good physical properties. These HA/PROT NPs also may be considered as a promising system for the delivery of compounds other than sCT.
stability, biocompatibility and potential use as peptide carriers, stability, biocompatibility and potential use as peptide carriers, Table 2   Table 2 . Composition, properties (TR -transmittance, PS -particle size, PDIpolydispersity index, ZP -zeta potential), association efficiency (AE), non- were 0.1 mg/ml and 7 BAEE/ml, respectively) (mean ± S.D., n = 4). 
